A Phase 2 Clinical Study of Pegerythropoietin Injection (RD01) for the Treatment of Anemia in Chronic Renal Failure Patients With Hemodialysis

Inclusion Criteria: * Patients with chronic renal failure who are undergoing maintenance hemodialysis for at least 12 weeks; * 18 ≤ age ≤ 75 years of age, male or female; * Patients who have received short-acting EPO treatment and meets the treatment standard (hemoglobin 100 \~ 120 g / L). The mean Hb value in the screening period (at least two weeks apart ) is within the range of 100 \~ 120 g / L (both ends). The difference is less than 10g / L; * Evaluation of iron status during the screening period, transferrin saturation (TSAT) ≥20% or serum ferritin (SF) ≥200 μg / L; * Evaluation of dialysis adequacy during the screening period, with SpKt / V≥1.2 or URR≥65%; * Subjects agree to use reliable contraceptives from the screening period to within 6 months after the last medication * Sign the informed consent. Exclusion Criteria: * Patients who have received or plan to have a kidney transplant during the study period * Except of renal anemia, there are other diseases that cause chronic anemia (such as sickle cell anemia, myelodysplastic syndrome, hematological malignancies, myeloma, hemolytic anemia, pure red blood cell aplastic anemia) * Patients with acute or chronic blood loss (such as upper gastrointestinal bleeding) in the past 3 months or patients who have undergone surgery with extensive bleeding, or patients who plan to undergo surgery during the study period * Patients with coagulation dysfunction (time to activate partial thromboplastin\> 1.5 times the upper limit of normal value) * The following circumstances (including but not limited to) during the screening, investigators evaluated that it is not suitable for enrollment: 1. Abnormal liver function (aspartate aminotransferase or alanine aminotransferase is more than 3 times the upper limit of normal value); 2. Patients who were positive for Hepatitis B surface antigen (HBsAg), hepatitis B core antigen (HBeAg), HIV antibody (HIV-Ab), hepatitis C virus antibody (HCV-Ab) or Treponema pallidum antibody; * Patients with severe secondary hyperparathyroidism (iPTH\> 1000 ng / L); * Patients with severe hypertension and poor control of blood pressure (systolic blood pressure\> 180 mmHg or diastolic blood pressure\> 100 mmHg) * Patients with severe thromboembolic disease * People with severe cardio-cerebral vascular disease (excluding luminal infarction), severe or unstable coronary artery disease, heart failure (NYHA III or IV) or myocardial infarction or stroke within 3 months * Patients with malignant tumors (excluding non-melanoma skin cancer or resected cancer in situ) * People with a history of severe allergies (including drug allergies), allergies to erythropoietin, or allergic to any component of the test drug (such as human serum albumin) * People with severe infection who are receiving systemic antibiotics * Patients who have received androgen therapy or blood transfusion therapy within the last 8 weeks; * Participated in other new drug clinical trials as a subject within 3 months or the withdrawal time was shorter than the 5 half-life of the test drug at the time of enrollment (whichever is the longest); * Patients with a history of seizures * Pregnant and lactating women * Alcohol, drug or drug addicts * Other situations that the researcher believes may affect validity judgment or are not suitable for participation.